Goldman Sachs
ORIC icon

Goldman Sachs’s Oric Pharmaceuticals ORIC Stock Holding History

Goldman Sachs’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Sell
1,475,712
-463,573
-24% -$5.26M ﹤0.01% 2490
2025
Q4 		$15.9M Buy
1,939,285
+1,034,473
+114% +$11.9M ﹤0.01% 2605
2025
Q3 		$10.9M Buy
904,812
+415,175
+85% +$4.37M ﹤0.01% 2878
2025
Q2 		$4.97M Buy
489,637
+194,853
+66% +$1.31M ﹤0.01% 3424
2025
Q1 		$1.64M Buy
294,784
+24,778
+9% +$217K ﹤0.01% 4318
2024
Q4 		$2.18M Sell
270,006
-52,619
-16% -$483K ﹤0.01% 4199
2024
Q3 		$3.31M Buy
322,625
+43,815
+16% +$433K ﹤0.01% 3716
2024
Q2 		$1.97M Buy
278,810
+109,132
+64% +$977K ﹤0.01% 3938
2024
Q1 		$2.33M Buy
169,678
+118,890
+234% +$1.41M ﹤0.01% 3764
2023
Q4 		$467K Buy
50,788
+2,632
+5% +$19K ﹤0.01% 4793
2023
Q3 		$291K Sell
48,156
-8,014
-14% -$65.7K ﹤0.01% 4901
2023
Q2 		$436K Sell
56,170
-38,149
-40% -$217K ﹤0.01% 4812
2023
Q1 		$538K Buy
+94,319
New +$493K ﹤0.01% 4778
2022
Q4 		– Sell
-27,557
Closed -$88K – 6193
2022
Q3 		$88K Sell
27,557
-34,830
-56% -$139K ﹤0.01% 5718
2022
Q2 		$280K Buy
62,387
+2,081
+3% +$8.3K ﹤0.01% 5462
2022
Q1 		$322K Buy
60,306
+16,391
+37% +$148K ﹤0.01% 5620
2021
Q4 		$645K Buy
43,915
+3,494
+9% +$54.5K ﹤0.01% 5191
2021
Q3 		$845K Buy
40,421
+6,718
+20% +$136K ﹤0.01% 4884
2021
Q2 		$596K Buy
33,703
+7,383
+28% +$162K ﹤0.01% 5112
2021
Q1 		$645K Buy
26,320
+8,498
+48% +$269K ﹤0.01% 4930
2020
Q4 		$603K Buy
17,822
+4,278
+32% +$123K ﹤0.01% 4501
2020
Q3 		$339K Buy
13,544
+3,280
+32% +$78.1K ﹤0.01% 4670
2020
Q2 		$346K Buy
+10,264
New +$328K ﹤0.01% 4559

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs's ORIC Position: Q1 2026 in Review

Goldman Sachs reduced its Oric Pharmaceuticals (ORIC) stake by 24% in Q1 2026, selling an estimated $5.26M and leaving 1,475,712 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Goldman Sachs first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Goldman Sachs held 1,475,712 shares of Oric Pharmaceuticals worth $18.7M as of Q1 2026.
  • Goldman Sachs sold 463,573 Oric Pharmaceuticals shares in Q1 2026, an estimated $5.26M.
  • Oric Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2490 holding.
  • Goldman Sachs first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.